TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06700096: An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B

Sponsor: Biocad · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$877,560

Rescue Site Savings

+$585,040

Unlock Full NCT06700096 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06700096 Rescue Dossier →